https://www.fiercebiotech.com/biotech/nkartas-blood-cancer-car-stalls-again-falling-response-rate-forcing-it-out-race
Nkarta raised $230 million on the back of 4 out 6 complete responses in an early cohort. However, they only had 1 more complete response in the next 13 high dosed patients.
- Forums
- ASX - By Stock
- CHM
- Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-39
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable